Abstract PS2-07-07: Relationship of early ctDNA dynamics with response to inavolisib alone or in combination with endocrine therapy +/- CDK4/6 inhibitor in PIK3CA-mutated HR+, HER2- metastatic breast cancer from the first-in-human phI/Ib trial
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: S. Hilz, M. K. Accordino, P. L. Bedard, A. Cervantes, V. Gambardella, E. P. Hamilton, A. Italiano, K. L. Jhaveri, D. Juric, K. Kalinsky, I. E. Krop, M. Oliveira, C. Saura, P. Schmid, N. C. Turner, E. S. Sokol, M. Childress, R. S. Huang, Z. J. Assaf, J. Aimi, S. Royer-Joo, J. L. Schutzman, K. E. Hutchinson
Institutions: Genentech, Columbia University Irving Medical Center, Columbia University, University of Toronto, Princess Margaret Cancer Centre, Universitat de València, Sarah Cannon, Université de Bordeaux, Institut Bergonié, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Emory University, Winship Cancer Institute, Yale Cancer Center, Yale University, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Queen Mary University of London, Barts Cancer Institute, Royal Marsden Hospital, Foundation Medicine (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129771733
Cites:
Cited by:
Related to: